Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: Block attenuation by mutations of the pore residues Y652 or F656

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 376, Issue 4, 2007, Pages 275-284

  Scholz, Eberhard P ^a   Konrad, Franziska M ^a   Weiss, Daniel L ^b   Zitron, Edgar ^a   Kiesecker, Claudia ^a   Bloehs, Ramona ^a   Kulzer, Martin ^a   Thomas, Dierk ^a   Kathöfer, Sven ^a   Bauer, Alexander ^a   Maurer, Martin H ^c   Seemann, Gunnar ^b   Katus, Hugo A ^a   Karle, Christoph A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF KARLSRUHE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acquired long QT syndrome; Anticholinergic; Arrhythmia; HERG; Human "Ether go go related gene" potassium channel; Orphenadrine; Repolarization

Indexed keywords

AMINO ACID; ANTIPARKINSON AGENT; MUTANT PROTEIN; ORPHENADRINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG;

ANTICHOLINERGIC EFFECT; ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE MUTATION; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; IC 50; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PATCH CLAMP; PROTEIN EXPRESSION; VOLTAGE CLAMP; WHOLE CELL; XENOPUS;

ANIMALS; ANTIPARKINSON AGENTS; CELL LINE; CHOLINERGIC ANTAGONISTS; CLONING, MOLECULAR; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HUMANS; MUTATION; OOCYTES; ORPHENADRINE; XENOPUS LAEVIS;

EID: 36448963090     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0202-6     Document Type: Article

References (31)

1. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA (1999) MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175-187
2. Altomare C, Terragni B, Brioschi C, Milanesi R, Pagliuca C, Viscomi C, Moroni A, Baruscotti M, DiFrancesco D (2003) Heteromeric HCN1-HCN4 channels: a comparison with native pacemaker channels from the rabbit sinoatrial node. J Physiol 549:347-359
3. Anantharam A, Lewis A, Panaghie G, Gordon E, McCrossan ZA, Lerner DJ, Abbott GW (2003) RNA interference reveals that endogenous Xenopus MinK-related peptides govern mammalian K+ channel function in oocyte expression studies. J Biol Chem 278:11739-11745
4. Barish ME (1983) A transient calcium-dependent chloride current in the immature Xenopus oocyte. J Physiol 342:309-325
5. Brocks DR (1999) Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharmacol Sci 2:39-46
6. Choe H, Nah KH, Lee SN, Lee HS, Lee HS, Jo SH, Leem CH, Jang YJ (2006) A novel hypothesis for the binding mode of HERG channel blockers. Biochem Biophys Res Commun 344:72-78
7. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803
8. Danze LK, Langdorf MI (1991) Reversal of orphenadrine-induced ventricular tachycardia with physostigmine. J Emerg Med 9:453-457
9. Dilaveris P, Pantazis A, Vlasseros J, Gialafos J (2001) Non-sustained ventricular tachycardia due to low-dose orphenadrine. Am J Med 111:418-419
10. Ellison T (1972) Metabolic studies of 3 H-orphenadrine citrate in the rat, dog and rhesus monkey. Arch Int Pharmacodyn Ther 195:213-230
11. Henderson RA, Lane S, Henry JA (1991) Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. Hum Exp Toxicol 10:59-62
12. Kiehn J, Lacerda AE, Brown AM (1999) Pathways of HERG inactivation. Am J Physiol 277:H199-H210
13. Kiesecker C, Zitron E, Lück S, Bloehs R, Scholz EP, Kathöfer S, Thomas D, Kreye VAW, Katus HA, Schoels W, Karle CA, Kiehn J (2004) Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action. Naunyn Schmiedebergs Arch Pharmacol 370:423-435
14. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P (1995) Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect 102:237-246
15. Labout JJ, Thijssen CT, Keijser GG, Hespe W (1982) Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. Eur J Clin Pharmacol 21:343-350
16. Lees A (2005) Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 22:731-740
17. Luzza F, Raffa S, Saporito F, Oreto G (2006) Torsades de pointes in congenital long QT syndrome following low-dose orphenadrine. Int J Clin Pract 60:606-608
18. Madeja M, Musshoff U, Speckmann EJ (1997) Follicular tissues reduce drug effects on ion channels in oocytes of Xenopus laevis. Eur J Neurosci 9:599-604
19. McDonald TV, Yu Z, Ming Z, Palma E, Meyers MB, Wang KW, Goldstein SA, Fishman GI (1997) A minK-HERG complex regulates the cardiac potassium current I(Kr). Nature 388:289-292
20. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333
21. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45
22. Sánchez-Chapula JA, Navarro-Polanco RA, Sanguinetti MC (2004) Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine. Naunyn Schmiedeberg's Arch Pharmacol 370:484-491
23. Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299-307
24. Scholz EP, Zitron E, Kiesecker C, Lueck S, Kathöfer S, Thomas D, Weretka S, Peth S, Kreye VAW, Schoels W, Katus HA, Kiehn J, Karle CA (2003) Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedeberg's Arch Pharmacol 368:404-414
25. Scholz EP, Zitron E, Kiesecker C, Lück S, Thomas D, Kathöfer S, Kreye VAW, Katus HA, Kiehn J, Schoels W, Karle CA (2005) Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation. Naunyn Schmiedeberg's Arch Pharmacol 371:516-525
26. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George ALJ, Goldstein SA (2000) A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 97:10613-10618
27. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J (2002) The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 300:543-548
28. Thomas D, Wu K, Kathöfer S, Katus HA, Schoels W, Kiehn J, Karle CA (2003) The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol 139:567-574
29. Thomas D, Hammerling BC, Wu K, Wimmer A, Ficker EK, Kirsch GE, Kochan MC, Wible BA, Scholz EP, Zitron E, Kathöfer S, Kreye VAW, Katus HA, Schoels W, Karle CA, Kiehn J (2004) Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol 142:485-494
30. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269:92-95
31. Van Herreweghe I, Mertens K, Maes V, Ramet J (1999) Orphenadrine poisoning in a child: clinical and analytical data. Intensive Care Med 25:1134-1136